Is the business good?
How good a business is URGN?
UroGen Pharma Ltd. keeps −77% of every revenue dollar as operating profit, against −72% for the median Biotechnology name.
−77%
Operating margin · Biotechnology median −72% · 12 months to Q1 2026
- R&D as % of revenue
- 45%
R&D as % of revenue
- Gross margin
- 90%
Gross margin
| Year | Operating margin |
|---|---|
| FY2020 | −1074% |
| FY2021 | −192% |
| FY2022 | −123% |
| FY2023 | −79% |
| FY2024 | −107% |
| FY2025 | −114% |
Details›
- Gross margin12 months to Q1 2026
- 90%
- Operating margin12 months to Q1 2026
- −77%
- Net margin12 months to Q1 2026
- −95%
- Free cash flow margin
- −118%
- R&D as % of revenue
- 45%
- Revenue, trailing twelve months
- $140M
- Free cash flow, trailing twelve months
- −$166M
- Net income, trailing twelve months
- −$133M
Margins, capital and share counts from the statements as filed with the SEC; cash conversion from the cash flow statement.